(Q34498299)

2 August 2017

title

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer (English)

1 reference

2 August 2017

1 reference

29

Masaki Mori

1 reference

2 August 2017

28

Yuichiro Doki

1 reference

2 August 2017

17

Hidetoshi Eguchi

1 reference

2 August 2017

1

Sumiyuki Nishida

1 reference

2 August 2017

8

Toshinori Ito

1 reference

2 August 2017

12

Yoshihiro Oka

1 reference

2 August 2017

22

Naoki Hosen

1 reference

2 August 2017

23

Yusuke Oji

1 reference

2 August 2017

Shigeo Koido

2

1 reference

2 August 2017

Yutaka Takeda

3

1 reference

2 August 2017

Sadamu Homma

4

1 reference

2 August 2017

Hideo Komita

5

1 reference

2 August 2017

Akitaka Takahara

6

1 reference

2 August 2017

Satoshi Morita

7

1 reference

2 August 2017

Soyoko Morimoto

9

1 reference

2 August 2017

Kazuma Hara

10

1 reference

2 August 2017

Akihiro Tsuboi

11

1 reference

2 August 2017

Satoru Yanagisawa

13

1 reference

2 August 2017

Yoichi Toyama

14

1 reference

2 August 2017

Masahiro Ikegami

15

1 reference

2 August 2017

Toru Kitagawa

16

1 reference

2 August 2017

Hiroshi Wada

18

1 reference

2 August 2017

Hiroaki Nagano

19

1 reference

2 August 2017

Jun Nakata

20

1 reference

2 August 2017

Yoshiki Nakae

21

1 reference

2 August 2017

Toshio Tanaka

24

1 reference

2 August 2017

Ichiro Kawase

25

1 reference

2 August 2017

Atsushi Kumanogoh

26

1 reference

2 August 2017

Junichi Sakamoto

27

1 reference

2 August 2017

Toshifumi Ohkusa

30

1 reference

2 August 2017

Hisao Tajiri

31

1 reference

2 August 2017

Haruo Sugiyama

32

1 reference

2 August 2017

publication date

1 February 2014

1 reference

2 August 2017

published in

Journal of Immunotherapy

1 reference

2 August 2017

volume

37

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

105-114

1 reference

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Cancer immunotherapy comes of age

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Advanced pancreatic carcinoma: current treatment and future challenges

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Use of tumour-responsive T cells as cancer treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Immunological aspects of cancer chemotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Combined chemoimmunotherapy of solid tumours: improving vaccines?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Pancreatic cancer and thromboembolic disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Cancer immunotherapy: moving beyond current vaccines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Phase I trial of gemcitabine in patients with advanced pancreatic cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229357

Immunity to WT1 in the animal model and in patients with acute myeloid leukemia

27 October 2018

1 reference

12 December 2020

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

1 reference

12 December 2020

WT1-specific serum antibodies in patients with leukemia

1 reference

12 December 2020

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

1 reference

12 December 2020

WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission

1 reference

12 December 2020

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease

1 reference

12 December 2020

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

1 reference

12 December 2020

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

12 December 2020

10.1097/CJI.0000000000000020

Identifiers

DOI

1 reference

release_tg3viy5us5csnpprw7fdm2jjlm

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tg3viy5us5csnpprw7fdm2jjlm

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4229357

1 reference

2 August 2017

1 reference